肝细胞-胆管细胞癌合并症的危险因素：一项基于医院的病例对照研究。
Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.
作者信息
Zhou Yan-Ming, Zhang Xiao-Feng, Wu Lu-Peng, Sui Cheng-Jun, Yang Jia-Mei
机构信息
Yan-Ming Zhou, Lu-Peng Wu, Department of Hepato-Biliary-Pancreato-Vascular Surgery, the First Affiliated Hospital of Xiamen University, Xiamen 361003, Fujian Province, China.
出版信息
World J Gastroenterol. 2014 Sep 21;20(35):12615-20. doi: 10.3748/wjg.v20.i35.12615.
Abstract
AIM
To identify risk factors contributing to the development of combined hepatocellular-cholangiocarcinoma (CHC) in China.
METHODS
One hundred and twenty-six patients with CHC and 4:1 matched healthy controls were interviewed during the period from February 2000 to October 2012. Logistic regression analysis was used to calculate odds ratios (OR) and 95% confidence intervals (CI) for each risk factor.
RESULTS
Univariate analysis showed that the significant risk factors for CHC development were hepatitis B virus (HBV) infection, heavy alcohol consumption, a family history of liver cancer, and diabetes mellitus. Multivariate stepwise logistic regression analysis showed that HBV infection (OR = 19.245, 95%CI: 13.260-27.931) and heavy alcohol consumption (OR = 2.186, 95%CI: 1.070-4.466) were independent factors contributing to the development of CHC.
CONCLUSION
HBV infection and heavy alcohol consumption may play a role in the development of CHC in China.
摘要
目的
确定在中国导致肝细胞-胆管细胞癌（CHC）发生的危险因素。
方法
在2000年2月至2012年10月期间，对126例CHC患者和4:1匹配的健康对照进行了访谈。采用逻辑回归分析计算每个危险因素的比值比（OR）和95%置信区间（CI）。
结果
单因素分析显示，CHC发生的显著危险因素为乙型肝炎病毒（HBV）感染、大量饮酒、肝癌家族史和糖尿病。多因素逐步逻辑回归分析显示，HBV感染（OR = 19.245，95%CI：13.260 - 27.931）和大量饮酒（OR = 2.186，95%CI：1.070 - 4.466）是导致CHC发生的独立因素。
结论
HBV感染和大量饮酒可能在中国CHC的发生中起作用。
相似文献
1
Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.肝细胞-胆管细胞癌合并症的危险因素：一项基于医院的病例对照研究。
World J Gastroenterol. 2014 Sep 21;20(35):12615-20. doi: 10.3748/wjg.v20.i35.12615.
2
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.肝内和肝外胆管癌的危险因素：一项基于医院的病例对照研究。
Am J Gastroenterol. 2007 May;102(5):1016-21. doi: 10.1111/j.1572-0241.2007.01104.x. Epub 2007 Feb 23.
3
Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study.肝内胆管细胞癌发生的危险因素：一项病例对照研究。
Hepatobiliary Pancreat Dis Int. 2011 Dec;10(6):626-31. doi: 10.1016/s1499-3872(11)60106-9.
4
Clinicopathological, radiologic, and molecular study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type.23例具有干细胞特征的胆管细胞型肝细胞-胆管细胞癌的临床病理、放射学及分子研究
Hum Pathol. 2017 Jun;64:118-127. doi: 10.1016/j.humpath.2017.01.016. Epub 2017 Apr 18.
5
Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.肝内胆管癌与丙型和乙型肝炎病毒感染、酒精摄入及肝内胆管结石：意大利的一项病例对照研究
Cancer Causes Control. 2001 Dec;12(10):959-64. doi: 10.1023/a:1013747228572.
6
Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study.韩国乙型肝炎病毒感染与肝内胆管癌：一项病例对照研究。
Am J Gastroenterol. 2008 Jul;103(7):1716-20. doi: 10.1111/j.1572-0241.2008.01796.x. Epub 2008 Jun 28.
7
Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea.乙型肝炎病毒感染、糖尿病及其在胆管癌发生中的协同作用：韩国的一项病例对照研究。
World J Gastroenterol. 2015 Jan 14;21(2):502-10. doi: 10.3748/wjg.v21.i2.502.
8
Combined hepatocellular cholangiocarcinoma: a case report and review of literature.肝内胆管癌合并肝细胞癌：一例报告及文献复习
Dig Dis Sci. 2013 Jul;58(7):2114-23. doi: 10.1007/s10620-013-2585-1. Epub 2013 Feb 9.
9
Debating the presentation, morphology, origin, and prognosis of a combined hepatocellular-cholangiocarcinoma.关于肝细胞-胆管癌的表现、形态学、起源及预后的讨论
Dig Dis Sci. 2013 Aug;58(8):2423-4. doi: 10.1007/s10620-013-2720-z. Epub 2013 May 22.
10
The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.肝细胞癌合并胆管细胞癌、肝细胞癌和肝内胆管细胞癌术后的临床特征和预后因素：倾向评分匹配分析。
Int J Med Sci. 2021 Jan 1;18(1):187-198. doi: 10.7150/ijms.50883. eCollection 2021.
引用本文的文献
1
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management.肝细胞-胆管细胞癌：生物学、诊断与管理
Liver Cancer. 2023 Apr 24;13(1):6-28. doi: 10.1159/000530700. eCollection 2024 Feb.
2
Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma.病例报告：阿替利珠单抗联合贝伐单抗治疗肝内胆管混合型肝癌
Front Oncol. 2023 Jul 21;13:1234113. doi: 10.3389/fonc.2023.1234113. eCollection 2023.
3
Non-invasive imaging in the diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma.联合肝细胞癌和胆管癌诊断中的非侵入性成像
Abdom Radiol (NY). 2023 Jun;48(6):2019-2037. doi: 10.1007/s00261-023-03879-0. Epub 2023 Mar 24.
4
The Diagnostic Approach towards Combined Hepatocellular-Cholangiocarcinoma-State of the Art and Future Perspectives.肝细胞-胆管细胞癌联合诊断方法——现状与未来展望
Cancers (Basel). 2023 Jan 1;15(1):301. doi: 10.3390/cancers15010301.
5
Analysis of viral integration reveals new insights of oncogenic mechanism in HBV-infected intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma.病毒整合分析揭示了乙型肝炎病毒感染的肝内胆管癌和肝细胞癌-胆管细胞癌合并癌中致癌机制的新见解。
Hepatol Int. 2022 Dec;16(6):1339-1352. doi: 10.1007/s12072-022-10419-3. Epub 2022 Sep 20.
6
A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab.一例接受阿替利珠单抗联合贝伐单抗治疗的不可切除型肝细胞癌合并胆管癌病例。
Clin Case Rep. 2022 Jul 25;10(7):e6129. doi: 10.1002/ccr3.6129. eCollection 2022 Jul.
7
Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know.肝细胞-胆管细胞癌：多学科团队应了解的内容。
Diagnostics (Basel). 2022 Apr 2;12(4):890. doi: 10.3390/diagnostics12040890.
8
Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma.胆管癌和肝内胆管癌的局部区域治疗
Cancers (Basel). 2021 Jul 2;13(13):3336. doi: 10.3390/cancers13133336.
9
Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma.与肝细胞癌合并胆管癌5年生存率相关的因素。
World J Hepatol. 2020 Nov 27;12(11):1020-1030. doi: 10.4254/wjh.v12.i11.1020.
10
New insights into the pathophysiology and clinical care of rare primary liver cancers.罕见原发性肝癌病理生理学与临床护理的新见解。
JHEP Rep. 2020 Aug 24;3(1):100174. doi: 10.1016/j.jhepr.2020.100174. eCollection 2021 Feb.
本文引用的文献
1
Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.根据最新的世界卫生组织分类，对肝细胞癌-胆管细胞癌联合癌进行临床病理分析。
Am J Surg Pathol. 2013 Apr;37(4):496-505. doi: 10.1097/PAS.0b013e31827332b0.
2
Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China.肝癌发病率在年轻人中显著降低：中国肝癌高发区病因学干预的 28 年随访。
Carcinogenesis. 2013 Aug;34(8):1800-5. doi: 10.1093/carcin/bgt007. Epub 2013 Jan 14.
3
Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma.临床病理因素影响肝癌合并胆管细胞癌切除术后的生存结局。
Surg Oncol. 2013 Mar;22(1):55-60. doi: 10.1016/j.suronc.2012.09.003. Epub 2012 Oct 24.
4
Comparison of clinical characteristics of combined hepatocellular-cholangiocarcinoma and other primary liver cancers.比较肝细胞癌-胆管细胞癌与其他原发性肝癌的临床特征。
J Gastroenterol Hepatol. 2013 Jan;28(1):122-7. doi: 10.1111/j.1440-1746.2012.07289.x.
5
Parallel induction of cell proliferation and inhibition of cell differentiation in hepatic progenitor cells by hepatitis B virus X gene.乙型肝炎病毒 X 基因诱导肝祖细胞增殖和抑制细胞分化的平行作用。
Int J Mol Med. 2012 Oct;30(4):842-8. doi: 10.3892/ijmm.2012.1060. Epub 2012 Jul 12.
6
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.肝细胞癌合并胆管细胞癌：临床特征、治疗方式和预后。
Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.
7
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma.原发性肝癌发病机制中是否存在共同因素？肝内胆管癌危险因素的荟萃分析。
J Hepatol. 2012 Jul;57(1):69-76. doi: 10.1016/j.jhep.2012.02.022. Epub 2012 Mar 13.
8
Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection.拉米夫定治疗对乙型肝炎病毒感染患者肝细胞癌发生率的长期影响。
J Gastroenterol. 2012 May;47(5):577-85. doi: 10.1007/s00535-011-0522-7. Epub 2012 Jan 11.
9
Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma.14 例肝细胞癌-胆管细胞癌混合型肝癌患者的临床病理分析。
Hepatobiliary Pancreat Dis Int. 2011 Dec;10(6):620-5. doi: 10.1016/s1499-3872(11)60105-7.
10
Combined hepatocellular-cholangiocarcinoma had poor outcomes after hepatectomy regardless of Allen and Lisa class or the predominance of intrahepatic cholangiocarcinoma cells within the tumor.联合肝细胞癌-胆管细胞癌无论在肝切除术后的 Allen 和 Lisa 分级或肿瘤内肝内胆管细胞癌细胞的优势方面，预后均较差。
Ann Surg Oncol. 2012 May;19(5):1628-36. doi: 10.1245/s10434-011-2150-0. Epub 2011 Nov 24.
Zotero 插件